lenalidomide

Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.

Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is a Lenalidomide-based Cereblon ligand that facilitates CRBN protein recruitment and can be linked to the protein's ligand via a linker, forming a PROTAC[1].

Lenalidomide-OH is an analog of Lenalidomide, a cereblon ligand for E3 ubiquitin ligase (CRBN), used for CRBN protein recruitment. It is able to attach to protein ligands using linkers to form PROTAC.

Lenalidomide-PEG3-iodine, an E3 ligase ligand-linker conjugate, consists of a cereblon-based Lenalidomide ligand and a 3-unit polyethylene glycol (PEG) linker. This compound is utilized in creating various proteolysis targeting chimeras (PROTACs), including the highly effective PROTAC BTK degrader SJF620, which has a degradation concentration 50 (DC50) of 7.9 nM[1].

Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride is a chemical compound comprising a cereblon (CRBN) ligand that functions as an E3 ubiquitin ligase, along with a linker. It is utilized to create the PROTAC MD-224[1].

Lenalidomide-propargyl-C2-NH2 hydrochloride is a compound that features a cereblon (CRBN) ligand for the E3 ubiquitin ligase, as well as a linker. It is utilized in the development of the PROTAC MD-224[1] system.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

Lenalidomide-5-Br is a Lenalidomide derivative that functions as a ligand for cereblon (CRBN), thereby facilitating the recruitment of CRBN protein. It can be conjugated to the protein ligand through a linker to generate a PROTAC molecule.

Lenalidomide-4-OH is a cereblon (CRBN) ligand derived from Lenalidomide, utilized in the recruitment of the CRBN protein. It can be conjugated to the protein ligand via a linker, facilitating the formation of PROTAC.

Lenalidomide-5-aminomethyl hydrochloride is a cereblon (CRBN) ligand derived from Lenalidomide. It serves as a ligand for the recruitment of the CRBN protein. When connected to the protein via a linker, Lenalidomide-5-aminomethyl hydrochloride forms a PROTAC.

Lenalidomide-C5-amido-Boc is a Cereblon ligand derived from Lenalidomide, and serves in the recruitment of CRBN protein. It can be effectively linked to the protein ligand through a linker, resulting in the formation of PROTAC.

Lenalidomide-I (Compound 72) is a derivative of the cereblon (CRBN) ligand, Lenalidomide, with affinity for E3 ubiquitin ligase. It facilitates the recruitment of CRBN protein. Lenalidomide-I can be utilized in PROTACs, such as the PROTAC BET degrader QCA570, by linking it to the targeted protein ligand through a linker.

Lenalidomide-6-F is a derivative of Lenalidomide that serves as a cereblon (CRBN) ligand facilitating the recruitment of CRBN protein. With the addition of a linker, Lenalidomide-6-F can be conjugated to the ligand for the protein, enabling the formation of PROTAC.

Lenalidomide-4-aminomethyl hydrochloride is a compound derived from Lenalidomide, serving as a cereblon (CRBN) ligand for the recruitment of CRBN protein. By connecting Lenalidomide-4-aminomethyl hydrochloride to the ligand via a linker, PROTAC formation can be facilitated.

Lenalidomide-4-aminomethyl is a CRBN ligand derived from Lenalidomide, which is utilized for the recruitment of CRBN protein. By linking Lenalidomide-4-aminomethyl to the ligand, a PROTAC can be formed.

Lenalidomide 4'-PEG2-azide, a Lenalidomide-derived Cereblon ligand, facilitates the recruitment of CRBN protein. This compound can be tethered via a linker to a protein ligand, enabling the formation of PROTAC [1].

Lenalidomide 4'-alkyl-C5-azide, a functionalized cerebellar ligand designed for PROTAC development, comprises an E3 ligand and an alkyl LC5 ligand featuring terminal azides for coupling with a target protein ligand [1].

Hydroxy lenalidomide, a metabolite of the thalidomide analog and anticancer agent lenalidomide, is a derivative substance involved in the metabolic process of its parent compound.

Lenalidomide hemihydrate is a derivative of Thalidomide, an orally active immunomodulator that acts as a molecular gel. It is a ligand for the ubiquitin E3 ligase cereblon, which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase.

Lenalidomide-Br (Compound 41), a derivative of Lenalidomide, acts as a ligand for cereblon (CRBN) - an E3 ubiquitin ligase involved in protein recruitment. This compound can be conjugated to a protein ligand via a linker to create PROTACs, such as the PROTAC STAT3 degrader SD-36.

Lenalidomide-C4-NH2 hydrochloride is a PROTAC linker that can be used to construct small-molecule linkers or PROTAC molecules to induce the degradation or regulation of target proteins. Lenalidomide-C4-NH2 hydrochloride acts as a ligand for the E3 ubiquitin ligase CRBN and is used to study protein degradation, signaling pathway regulation, and pharmacological mechanisms.

Lenalidomide-PEG1-azide is an E3 ligase ligand-linker complex comprising a cereblon ligand and linker, suitable for synthesising PROTACs and click chemistry reactions.

C5 Lenalidomide is an chemical weith inconclusive biological activity.

(3S)Lenalidomide-5-Br is a ligand for E3 ubiquitin ligases (Ligands for E3 Ligase). It is utilized in the synthesis of PROTACCbl-b-IN-1.